Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Marcel P, Trefny"'
Autor:
Marcel P. Trefny, Nicole Kirchhammer, Priska Auf der Maur, Marina Natoli, Dominic Schmid, Markus Germann, Laura Fernandez Rodriguez, Petra Herzig, Jonas Lötscher, Maryam Akrami, Jane C. Stinchcombe, Michal A. Stanczak, Andreas Zingg, Melanie Buchi, Julien Roux, Romina Marone, Leyla Don, Didier Lardinois, Mark Wiese, Lukas T. Jeker, Mohamed Bentires-Alj, Jérémie Rossy, Daniela S. Thommen, Gillian M. Griffiths, Heinz Läubli, Christoph Hess, Alfred Zippelius
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-21 (2023)
The efficacy of T-cell-based cancer immunotherapies can be compromised by T cell exhaustion. Here the authors develop a human ex vivo exhaustion model and, based on a CRISPR-Cas9 screen, identify SNX9 as a regulator of T cell exhaustion, showing that
Externí odkaz:
https://doaj.org/article/fdf4b11832574e5fbfe57578d57e0309
Autor:
Alfred Zippelius, Mélanie Buchi, Richard Klar, Julia Festag, Sven Michel, Frank Jaschinski, Sebastian Kobold, Abhishek S Kashyap, Johannes vom Berg, Laura Fernandez-Rodriguez, Chiara Cianciaruso, Ruben Bill, Marcel P Trefny, Nicole Kirchhammer, Rainer H Kohler, Elham Jones, Andre Maaske, Karen O Dixon, Mikael J Pittet
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 5 (2023)
Background Although immune checkpoint inhibitors have been a breakthrough in clinical oncology, these therapies fail to produce durable responses in a significant fraction of patients. This lack of long-term efficacy may be due to a poor pre-existing
Externí odkaz:
https://doaj.org/article/78cf6c8515374d7f847b8913a986bde6
Autor:
Abhishek S. Kashyap, Laura Fernandez-Rodriguez, Yun Zhao, Gianni Monaco, Marcel P. Trefny, Naohiro Yoshida, Kea Martin, Ashwani Sharma, Natacha Olieric, Pankaj Shah, Michal Stanczak, Nicole Kirchhammer, Sung-Moo Park, Sebastien Wieckowski, Heinz Laubli, Rachid Zagani, Benjamin Kasenda, Michel O. Steinmetz, Hans-Christian Reinecker, Alfred Zippelius
Publikováno v:
Cell Reports, Vol 28, Iss 13, Pp 3367-3380.e8 (2019)
Summary: Dendritic cell (DC) activation is a critical step for anti-tumor T cell responses. Certain chemotherapeutics can influence DC function. Here we demonstrate that chemotherapy capable of microtubule destabilization has direct effects on DC fun
Externí odkaz:
https://doaj.org/article/21a0d97cff3b46a0a90aae9154512253
Autor:
Alexander Kirchmair, Niloofar Nemati, Giorgia Lamberti, Marcel P. Trefny, Anne Krogsdam, Anita Siller, Paul Hörtnagl, Petra Schumacher, Sieghart Sopper, Adolf M. Sandbichler, Alfred Zippelius, Bart Ghesquière, Zlatko Trajanoski
Naïve T cells remain in an actively maintained state of quiescence until activation by antigenic signals, upon which they start proliferation and generation of effector cells to initiate a functional immune response. Metabolic reprogramming is essen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d4b8199e3100bef1c2c0d2d041baf160
https://doi.org/10.1101/2023.05.18.541159
https://doi.org/10.1101/2023.05.18.541159
Autor:
Heinz Läubli, Alfred Zippelius, Kirsten D. Mertz, Lukas Flatz, Zlatko Trajanoski, Martin Früh, Frank Stenner, Stefan Schaub, Ilaria Alborelli, Philip Jermann, Spasenija Savic, Florian Geier, Daniela S. Thommen, Severin Poechtrager, Petra Herzig, Monika Kaiser, Abhishek S. Kashyap, Fiamma Berner, Michal A. Stanczak, Benjamin Kasenda, Dietmar Rieder, Franziska Uhlenbrock, Sacha I. Rothschild, Marcel P. Trefny
Supplementary Methods and Data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8610d31879e1b10285c161940f55206
https://doi.org/10.1158/1078-0432.22468670
https://doi.org/10.1158/1078-0432.22468670
Autor:
Heinz Läubli, Alfred Zippelius, Kirsten D. Mertz, Lukas Flatz, Zlatko Trajanoski, Martin Früh, Frank Stenner, Stefan Schaub, Ilaria Alborelli, Philip Jermann, Spasenija Savic, Florian Geier, Daniela S. Thommen, Severin Poechtrager, Petra Herzig, Monika Kaiser, Abhishek S. Kashyap, Fiamma Berner, Michal A. Stanczak, Benjamin Kasenda, Dietmar Rieder, Franziska Uhlenbrock, Sacha I. Rothschild, Marcel P. Trefny
Purpose:PD-(L)1–blocking antibodies have clinical activity in metastatic non–small cell lung cancer (NSCLC) and mediate durable tumor remissions. However, the majority of patients are resistant to PD-(L)1 blockade. Understanding mechanisms of pri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ab3d158ae21e7bc8b03fa1743907d49
https://doi.org/10.1158/1078-0432.c.6527030.v1
https://doi.org/10.1158/1078-0432.c.6527030.v1
Autor:
Michal A. Stanczak, Natalia Rodrigues Mantuano, Nicole Kirchhammer, David E. Sanin, Francis Jacob, Ricardo Coelho, Arun V. Everest-Dass, Jinyu Wang, Marcel P. Trefny, Gianni Monaco, Anne Bärenwaldt, Melissa A. Gray, Adam Petrone, Abhishek S. Kashyap, Katharina Glatz, Benjamin Kasenda, Karl Normington, James Broderick, Li Peng, Oliver M.T. Pearce, Erika L. Pearce, Carolyn R. Bertozzi, Alfred Zippelius, Heinz Läubli
Publikováno v:
Science translational medicine : integrating medicine and science / American Association for the Advancement of Science
Immune checkpoint blockade (ICB) has substantially improved the prognosis of patients with cancer, but the majority experiences limited benefit, supporting the need for new therapeutic approaches. Up-regulation of sialic acid–containing glycans, te
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1cf1cc95f03c3acafab0e98d4e5bc3c
https://pubmed.ncbi.nlm.nih.gov/36322632
https://pubmed.ncbi.nlm.nih.gov/36322632
Autor:
Laura Fernandez-Rodriguez, Chiara Cianciaruso, Ruben Bill, Marcel P Trefny, Richard Klar, Nicole Kirchhammer, Mélanie Buchi, Julia Festag, Sven Michel, Rainer H Kohler, Elham Jones, Andre Maaske, Abhishek S Kashyap, Frank Jaschinski, Karen O Dixon, Mikael J Pittet, Alfred Zippelius
Publikováno v:
Journal for ImmunoTherapy of Cancer. 11:e006714
BackgroundAlthough immune checkpoint inhibitors have been a breakthrough in clinical oncology, these therapies fail to produce durable responses in a significant fraction of patients. This lack of long-term efficacy may be due to a poor pre-existing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0cd37b383ac0ffe8c7064ee151e6bdb6
https://doi.org/10.1136/jitc-2023-006714
https://doi.org/10.1136/jitc-2023-006714
Autor:
Nicole Kirchhammer, Marcel P. Trefny, Marina Natoli, Dominik Brücher, Sheena N. Smith, Franziska Werner, Victoria Koch, David Schreiner, Ewelina Bartoszek, Mélanie Buchi, Markus Schmid, Daniel Breu, K. Patricia Hartmann, Polina Zaytseva, Daniela S. Thommen, Heinz Läubli, Jan P. Böttcher, Michal A. Stanczak, Abhishek S. Kashyap, Andreas Plückthun, Alfred Zippelius
T cell–directed cancer immunotherapy often fails to generate lasting tumor control. Harnessing additional effectors of the immune response against tumors may strengthen the clinical benefit of immunotherapies. Here, we demonstrate that therapeutic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::057aa2b1cc1e6a23fbbeec3ddb22cbba
Autor:
Marcel P. Trefny, Zlatko Trajanoski, Spasenija Savic, Petra Herzig, Sacha I. Rothschild, Kirsten D. Mertz, Stefan Schaub, Fiamma Berner, Franziska Uhlenbrock, Martin Früh, Benjamin Kasenda, Ilaria Alborelli, Lukas Flatz, Dietmar Rieder, Florian Geier, Severin Poechtrager, Michal A. Stanczak, Philip Jermann, Heinz Läubli, Monika Kaiser, Alfred Zippelius, Abhishek S. Kashyap, Daniela S. Thommen, Frank Stenner
Publikováno v:
Clinical Cancer Research. 25:3026-3034
Purpose: PD-(L)1–blocking antibodies have clinical activity in metastatic non–small cell lung cancer (NSCLC) and mediate durable tumor remissions. However, the majority of patients are resistant to PD-(L)1 blockade. Understanding mechanisms of pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5b82d01d1a303de87b59f7533b7d2a1
https://doi.org/10.1158/1078-0432.ccr-18-3041
https://doi.org/10.1158/1078-0432.ccr-18-3041